Health Care • Medical/Nursing Services
$2.32 ▲ +0.09
(+4.04%)
MKT CAP: $111.8M • VOL: 739.7K
52W L $2 52W H $6
LFMD // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $194.1M | $154.8M | $152.5M |
| YoY Revenue Growth % | +25.3% | +1.5% | — |
| Gross Profit | $166.3M | $133.4M | — |
| Gross Margin % | 85.7% | 86.2% | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | -$7.7M | -$20.4M | -$14.5M |
| Operating Margin % | -4.0% | -13.2% | -9.5% |
| Net Income (GAAP) | -$11.2M | $24.5M | $17.8M |
| EBITDA (Normalized) | -$6.2M | -$19.2M | — |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | $8.3M | $17.5M | $8.8M |
| Capital Expenditures (CapEx) | $1.9M | $1.5M | — |
| Free Cash Flow (FCF) | $6.4M | $16.0M | $8.8M |
| FCF Margin % | 3.3% | 10.4% | 5.8% |
| Return on Invested Capital (ROIC %) | -26.2% | -45.0% | — |
| Cash & Short-Term Equivalents | — | $35.0M | — |
| Total Debt (Short + Long Term) | — | — | — |
| Total Stockholders' Equity | $23.2M | -$9.1M | — |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR LFMD.